Entresto’s heart failure miss may not signal the end, given FDA’s openness to new endpoints

Despite narrowly missing its primary endpoint in the PARAGON-HF trial to treat heart failure patients with preserved ejection fraction, Entresto’s performance on secondary endpoints suggests the drug could still have a path forward in the population, which currently lacks any approved therapies.

Novartis AG (NYSE:NVS; SIX:NOVN) reported Sunday

Read the full 479 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE